#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor
Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey pharma company is ...
May 29, 2026 08:00 AM EDTUpdated 01:30 PM R&D Bristol Myers details Phase 3 trial win for Pomalyst successor Lei Lei Wu News Reporter Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that